All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Filters

94 (0,153s)

Result

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Venetoclax is an effective therapy for chronic lymphocytic leukemia (CLL) with the potential to induce deep remissions.1-5 Furthermore, venetoclax in combination).2 As fixed-duration venetoclax-based therapies are increas...

Hematology

  • 2022
  • Jimp
  • Link
Result

VENETOCLAX WITH AZACYTIDINE IN THE TREATMENT OF MOLECULAR RELAPSE OF ACUTE MYELOID LEUKEMIA

VENETOCLAX WITH AZACYTIDINE IN THE TREATMENT OF MOLECULAR RELAPSE OF ACUTE MYELOID LEUKEMIA - conference abstract.

Hematology

  • 2024
  • O
Result

WHAT IS THE REAL FATE OF “UNFIT” ACUTE MYELOID LEUKEMIA (AML) PATIENTS IN THE VENETOCLAX ERA?

WHAT IS THE REAL FATE OF “UNFIT” ACUTE MYELOID LEUKEMIA (AML) PATIENTS IN THE VENETOCLAX ERA? - conference abstract.

Hematology

  • 2024
  • O
Result

Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy.

Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy - conference abstract....

Hematology

  • 2023
  • O
Result

Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status

Venetoclax, a BCL2 inhibitor, has a promising single-agent activity in mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and large B-cell lymphomas we demonstrated strong synergy between venetoclax and A1155463, a BCL-...

Hematology

  • 2024
  • Jimp
  • Link
Result

VENETOCLAX + AZACYTIDINE THERAPY IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) RARELY RESULTS IN THE ELIMINATION OF THE LEUKAEMIC CLONE, EVEN WHEN MORPHOLOGICAL REMISSION IS PRESENT

VENETOCLAX + AZACYTIDINE THERAPY IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) RARELY RESULTS IN THE ELIMINATION OF THE LEUKAEMIC CLONE, EVEN WHEN MORPHOLOGICAL REMISSION IS PRESENT - conference abstract....

Hematology

  • 2024
  • O
Result

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

to venetoclax had promising efficacy in a previous phase 1b study. Methods: We randomly of age or older, or both to azacitidine plus either venetoclax or placebo. All); venetoclax (target dose, 400 mg) or matching placebo ...

Hematology

  • 2020
  • Jimp
  • Link
Result

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma

Purpose: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over) expression of BCL2. A BCL2-targeting drug, venetoclax, has promising anticancer activity in MCL. We analyzed molecular mecha...

Oncology

  • 2019
  • Jimp
  • Link
Result

Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

Venetoclax-azacitidine is approved for treatment of patients with newly with venetoclax-azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax...

Hematology

  • 2024
  • Jimp
  • Link
Result

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma

Purpose: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over) expression of BCL2. A BCL2-targeting drug, venetoclax, has promising anticancer activity in MCL. We analyzed molecular mecha...

Biochemistry and molecular biology

  • 2019
  • Jimp
  • Link
  • 1 - 10 out of 94